Patient survival following arteriovenous fistula formation


Published in:
The journal of vascular access

Document Version:
Peer reviewed version

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
© 2015 Wichtig Publishing

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Patient survival following arteriovenous fistula formation

Authors
Damian G McGrogan
Melanie A Field
Alexander P Maxwell
Yazin Marie
Nicholas G Inston

Institution
1. Department of Vascular Access and Renal Transplantation, University Hospitals Birmingham, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH.
2. Regional Nephrology Unit, Belfast Health and Social Care Trust, Belfast City Hospital, 51 Lisburn Road, Belfast, BT9 7AB and School of Medicine, Dentistry and Biomedical Sciences, Health Sciences Building, 97 Lisburn Road, Belfast BT9 7BL.

Corresponding author
Damian McGrogan, Department of Vascular Access and Renal Transplantation, University Hospitals Birmingham, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH. Tel: 0044121 627 2000
E-mail: damianmcg@gmail.com; damian.mcgrogan@uhb.nhs.uk

Sources of financial support: No competing interest compared

Type of article for submission Original manuscript
ABSTRACT

Purpose:
Efforts to promote arteriovenous fistulas (AVFs) have been successful in increasing the prevalence of AVF use as the primary vascular access for haemodialysis HD. Sustained preference for AVF use may not be the most appropriate vascular access choice for all patient groups. Arteriovenous grafts (AVGs) offer advantages of earlier use and lower primary failure rates compared to AVFs so may be preferable for patients where short term vascular access is needed. This study was designed to assess comparative mortality in different age groups following AVF formation.

Methods:
A prospective cohort of patients having AVF creation was recruited. Patients were subdivided into three age groups; Group A: < 50 years; Group B: 50-74 years and Group C: ≥ 75 years. Survival curves and Cox regression analysis was performed on each of these groups.

Results:
One hundred and thirty-four patients (n=134) were recruited into the study. The prevalence of diabetes increased significantly with age. As expected, mortality was higher in older age groups (log rank (mantel cox) 19.227; p = 0.0001). Mortality rates at one year were 0% in group A, 12.5% in group B and 29.1% in group C. Medium term mortality at four years was 7.9% in group A, 39.1% in group B and 54.8% in group C.

Conclusions:
We found a significantly higher mortality rate in patients ≥75 years in comparison to those <75 years. The choice of vascular access modality should be tailored to the individual with particular reference to the patient’s expected survival.
Keywords

arteriovenous fistula; elderly; haemodialysis; mortality
INTRODUCTION

The prevalent use of arteriovenous fistulas (AVFs) has increased reflecting initiatives such as Fistula First (http://www.fistulafirst.org/) and promotion of AVFs as the vascular access of choice in national guidelines.(1,2,3,4) The improvement in AVF prevalence is a welcome trend however older patients could be disadvantaged by repeated unsuccessful attempts at surgical AVF creation and resulting overdependence on central venous catheters (CVCs).(5) The age structure of the end-stage renal disease (ESRD) population has changed considerably over the past 20 years with an increasing proportion of older patients (>75 years) receiving dialysis.(6,7,8) Furthermore the progression of chronic kidney disease is typically slower and less predictable in older patients. This can mean in practice that is difficult to ensure timely provision of vascular access for older patients. The significant increase in the number of elderly dialysis patients and the unique challenges they represent for vascular access provision are poorly reflected in guidelines regarding vascular access formation. (1,2,3,4) This is also emphasised in a recent review by Fassett and colleagues(9) of palliative care in ESRD suggesting there is a paucity of robust evidence to predict the outcomes in elderly patients who commence dialysis and therefore decisions regarding their best management remain difficult.

Worldwide, the number of elderly patients with ESRD commencing haemodialysis is rising. In the USA, since 2000, the adjusted incident rate for dialysis in patients aged ≥75 years has increased by 12.2%.(6) In Canada, the number of incident patients with ESRD aged ≥75 years doubled between 1996 and 2005 whilst the number of incident patients with ESRD aged 20–64 years has decreased in the corresponding
years.(7) In the UK, from 2005 to 2008, the number of patients on dialysis aged ≥65 years increased by 29% compared with an increase of only 16% in those aged 18–65 years.(8)

Important factors associated with AVF failure in those patients >67 years of age include increasing age, female gender, black race, diabetes, cardiac failure and shorter pre-ESRD nephrology care.(10)

Optimal timing of referral for AVF formation is a complex issue in the management of patients with ESRD. Advanced age has been shown to be a risk factor for late referral to nephrologist, increased use of CVCs and increased likelihood of hospital admission, septicaemia and higher mortality.(11,12) It would therefore be important to stratify these patients into groups and decide dialysis needs according to individual profiles and patient preferences rather than a Fistula First “one size fits all” policy.

We sought to prospectively assess the age-related mortality of patients following surgical creation of an AVF and identify the factors contributing to higher mortality rates.

SUBJECTS AND METHODS

A prospective cohort study was designed and recruited consecutive patients undergoing single incision (radiocephalic, brachiocephalic and first stage brachiobasilic) AVF formation between 8th April 2009 and 30th September 2009. Patients are referred to the vascular access unit following weekly multi-disciplinary team discussions identifying patients who are showing rapid progression of renal
disease with a glomerular filtration rate of < 15 mL/min/1.73m² or < 20 mL/min/1.73m² for patients with diabetes. All surgery was performed in a single centre (Queen Elizabeth Hospital, Birmingham, UK) and all operations were carried out by or under the direct supervision of four consultant surgeons. Information was collated in a vascular access database and included patient age, past medical history, pre-operative haemoglobin concentration, international normalised ratio, systolic and diastolic blood pressures, anticoagulant medications, grade of operating surgeon, type of AVF formed, pre-operative vessel measurements made with Doppler ultrasound assessment and dialysis status. Vessels considered suitable for AVF formation were based on intraluminal size criteria (2 mm for artery and 2.5 mm for vein) and vessel patency. This patient cohort was followed up until 10th August 2013 with outcomes documented focusing on date of death. No system is currently in place within our unit for surveillance of AVF which are found to have achieved radiological adequacy at six weeks but not yet used for dialysis. The study was approved by local audit review board (CARMS-11315) where specific patient consent was not deemed necessary as it was non-interventional and observational. Data was collected and analysed from the electronic patient database using clinical data collected as standard and not study specific. This database is also updated from primary care to ensure all deaths of patients are recorded. Patients were subdivided into age groups accordingly; Group A: < 50 years; Group B: 50-74 years and Group C: ≥75 years of age. Survival analysis was then performed using SPSS 20 for each of these age groups. Cox regression analysis was used to identify clinical factors which impacted upon survival.
RESULTS

A total of 147 patients were included in the study. Nine patients were excluded after they underwent a second stage brachiobasilic operation. Two patients were excluded since their operations were for complications of a previously formed fistula (ligation of their AVF; one for aneurysmal development and one for vascular steal). Two further patients were excluded since they had an AVG inserted. This left 134 patients available for survival analysis. Seven patients had their operations performed under general anaesthetic and 127 patients underwent their procedure under local anaesthetic.

Cause of end-stage renal disease (ESRD)

Of the 134 patients included, 32 (23.9%) had diabetes documented as a cause of ESRD. Twenty-three (17.2%) had an unknown cause, 17 (12.7%) had glomerulonephritis, 11 (8.2%) had hypertension, 6 (4.5%) had small kidneys, 8 (5.9%) had polycystic kidney disease, 5 (3.7%) had reflux nephropathy and 7 (5.2%) had renovascular disease documented as the cause of ESRD. The remaining 25 (18.7%) had documented diagnoses of amyloidosis, myeloma, obstructive nephropathy, abdominal aortic aneurysm repair, bilateral nephrectomies for renal cell carcinoma, calcineurin inhibitor toxicity, juvenile nephronophthisis, nephrolithiasis, microscopic polyangiitis, post cystectomy for transitional cell carcinoma, renal dysplasia, renal tuberculosis and scleroderma.

Ethnicity
Eighty-nine (66.4%) patients were white, 29 (21.6%) were Indo-Asian, 12 (9.0%) were black, two (1.5%) were of mixed ethnicity and two (1.5%) patients were Chinese.

Past medical history and medications
Prevalence of hypertension and diabetes for the entire cohort was 68.7% (92 patients) and 35.1% (47 patients) respectively. Eleven patients (8.2%) had previously undergone a renal transplant and six (4.5%) had a documented history of peripheral vascular disease. Thirty-nine patients (29.1%) were on aspirin, seven (5.2%) were on clopidogrel and 16 (11.9%) were on warfarin.

Types of arteriovenous fistula formed
Sixty two patients (46.3%) had radiocephalic AVFs, 54 (40.3%) had brachiocephalic AVFs and 18 (13.4%) had first stage brachiobasilic AVFs formed.

Dialysis status
Sixty-one patients (45.5%) were pre-dialysis, 73 were (54.5%) had already commenced dialysis.

Function
Early patency defined as a patent AVF at six week postoperative review was established in 113 (84.3%) patients and 77 (53.8%) subsequently used for dialysis. No attempt was made to monitor or salvage AVF which failed prior to the six week post-operative review.

Sub-group analysis
Table I shows the demographics of patients according to age groups. Thirty-eight (28.4%) patients in group A; 65 (48.5%) in group B; and 31 (23.1%) in group C.

**Survival analysis**

As expected, mortality was significantly higher with increasing age (log rank (mantel cox) 19.227; P = 0.0001). Figure 1 shows mortality rates for each age group. Mortality rates over 4 years were 7.9% in group A, 38.5% in group B and 54.8% in group C. The cumulative survival for each group from year 1 to year 4 is shown in Table II. Mortality rates were not significantly different if patients had commenced dialysis by the time of AVF creation or not. Cox regression analysis for the different variables confirmed that age and diabetes are associated with increased risk of death. In comparison to group A, group B (HR 5.1, CI 1.5-17.2; P=0.009) and group C (HR 8.7, CI 2.5-30.5; P=0.001) had an increased risk of death. The increased mortality risk with diabetes was not statistically significant (HR 1.5, CI 0.8-2.7; P=0.197). Gender, ethnicity, hypertension were not associated with an increased risk of death. Peripheral vascular disease was associated with an increased risk of death (HR 2.9, CI 1.0-8.1; P=0.043) however less than 5% of patients had documented history of peripheral vascular disease.

**DISCUSSION**

This prospective study demonstrates that older patients referred for AVF surgery have poorer survival compared to younger patients during a four year follow up period. Although this finding is to be expected, reflecting the impact of advancing age
with associated multiple co-morbidities upon patient survival, it is relevant when
deciding on the optimal vascular access procedure for older patients.

The UK Renal Registry 16th Annual Report (13) states that the most common
primary renal diagnosis for ESRD in the 2012 incident cohort was diabetes (25.6%),
followed by other (17.7%), unknown aetiology (15.9%), glomerulonephritis (14%),
hypertension (7.4%) and polycystic kidney disease (6.7%). UK Renal Registry data
also shows 70.8% of incident renal replacement therapy patients to be white, 22.7%
to be South Asian, 5.1% to be black and 1.4% other. The causes of incident ESRD
and background ethnicity are similar in our cohort. For instance, the prevalence of
diabetes (35.1%) and peripheral vascular disease (4.5%) in our cohort is very similar
to UK Renal Registry data showing an overall prevalence of diabetes at 34.8%, and
claudication at 6%. Our data is therefore largely representative of the UK population
reported in nationally published annual data.(13)

In this cohort a higher number of radiocephalic AVFs (46.3%) were formed than
brachiocephalic AVFs (40.3%) and first stage brachiobasilic AVFs (7.5%). This range
of AVFs formed is reflective of a larger retrospective cohort published by Weale and
colleagues (14) where more radiocephalic (53.9%) AVFs were formed than
brachiocephalic AVFs (46.1%).

Sub-group analysis

Diabetes was statistically more prevalent in the over 50 years of age groups.
Hypertension was found to be prevalent throughout all age groups and antiplatelet
and antithrombotic agent use increased with increasing age undoubtedly reflecting
the higher incidence of cardiovascular co-morbidities seen in the aging population.
Ethnic background was similar in all age groups. Age did not impact on the type of
AVF created however in our centre we use Doppler ultrasound measurements to assess blood vessel suitability for AVF formation and therefore do not discriminate by age alone.

Oliva and colleagues (15) report a four year survival of haemodialysis patients over 75 years of age as 39.6%. They compared mortality rates between less than 60 years, 60-75 years and 75 years and over. They found a significantly higher mortality in elderly (>75 years) patients with a cumulative survival of 83.1%, 68.3%, 53.5% and 39.6% after years 1, 2, 3, and 4. We found our cumulative survival rates in patients over 75 years to be 71.0%, 58.1%, 51.6% and 41.9% after years 1, 2, 3 and 4 respectively. Interestingly, Oliva and colleagues admit to some biasing of the data since they excluded the 71 patients who died within 90 days of commencing haemodialysis. Our data shows that a substantial number of deaths occur early in patients being referred for vascular access procedures. Approximately 42% of those over 75 years of age died within 2 years of being referred for a fistula. UK life expectancy data published in 2002 states that at 70 years of age males can expect to live for a further 14.7 years and females 17 years. Similarly for persons of 80 years of age life expectancy is 7.7 years for males and 9.1 years for females. (16)

The median survival of our cohort over 75 years is approximately 3 years confirming a shorter life expectancy in the presence of ESRD for those patients referred for fistula formation.

The high primary failure rate for AVFs is a very important issue in the elderly population. The length of time between referral for access formation and surgical procedure has been reported by Rayner and colleagues (17) to be longer than four weeks in 60% of patients referred, a conclusion that has been subsequently
supported by Ethier at al. (18) The major advantage of CVCs is that they can be used immediately for dialysis. This advantage has been extended more recently to AVGs specifically designed for use in vascular access surgery as some may be ready for use within 24 hours of insertion. The combined advantage of early cannulation of an AVG and reduced incidence of bloodstream infections (compared to CVCs) means that an AVG may offer the best compromise for vascular access in older patients with limited expected survival.

A critical point emphasized in the paper by Allon and Lok (19) is the inclusion of primary failures in the analysis of AVF compared to AVG. Once primary failure is included overall outcomes are equivalent or better for AVGs compared to AVFs up to 18 months following the initial vascular access surgery. AVGs have been shown to have significantly less primary failures, require fewer interventions to achieve patency and are associated with shorter duration of CVC dependence and CVC-related infections. AVGs are however associated with poorer cumulative survival compared with AVFs and require more interventions to maintain patency. (20) These conclusions are supported by Oliver at al. (21) who observed a longer period of CVC-dependence and superior patency of AVFs overall but comparable survival when primary failures are included. Indeed, a recent report from the USA has shown the Fistula First Breakthrough Initiative implementation to have increased the use of CVCs with any increased emphasis on in the placement of AVFs coming at the expense of AVGs rather than CVCs. (22) This has been argued to be a reflection of the increased use of CVCs as a temporary bridging measure to allow maturation of AVFs. (23)
The factors shown by Oliva and colleagues to be associated with an increased mortality were low BMI, CVC as initial vascular access, arterial hypertension, congestive heart failure, late referral to nephrologist, serum albumin level below 3.5 g/dL, Kt/V <1.2 and time of dialysis session less than 180 minutes. The multivariate model found that congestive heart failure, Kt/V <1.2 and serum albumin level <3.5 g/dL remained as independent predictors of mortality in those dialysis patients greater than 75 years of age. (15) We found in our cohort that age and peripheral vascular disease to be the only factors associated with significantly increased risk of death.

Limitations

This is a relatively small cohort of patients however we have shown the demographics to be representative of nationally published reports. A larger national cohort would further support the conclusions drawn here and allow for identification of patient related factors which correlate with a less than two year survival.

Conclusion

Our results show that elderly patients (>75 years) are much more likely to die within a 2 year period than those less than 75 years of age. In an older population a more tailored approach to vascular access creation is necessary. This study supports an AVG as a suitable first access by demonstrating that survival after AVF formation, whether successful or not is limited and rapid access from an AVG, with avoidance of CVC, is a pragmatic alternative approach to providing vascular access for elderly haemodialysis patients.

Conflict of interest
None to declare.
REFERENCES


Figure 1: Time to death following formation of fistula according to age.
Table I: Demographics of patients according to age groups.

<table>
<thead>
<tr>
<th></th>
<th>Group A (&lt;50 years)</th>
<th>Group B (50–74 years)</th>
<th>Group C (&gt;75 years)</th>
<th>P value</th>
<th>Student’s t-test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients (%)</td>
<td>38 (28.4)</td>
<td>65 (48.5%)</td>
<td>31 (23.1%)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Sex, male %</td>
<td>60.5</td>
<td>66.2</td>
<td>74.9</td>
<td>0.488</td>
<td></td>
</tr>
<tr>
<td>Ethnicity&lt;sup&gt;a&lt;/sup&gt;</td>
<td>23/10/4/1/0</td>
<td>43/13/6/1/2</td>
<td>23/6/2/0/0</td>
<td>0.832</td>
<td></td>
</tr>
<tr>
<td>W/A/B/M/C</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes %</td>
<td>13.2</td>
<td>42.2</td>
<td>48.4</td>
<td>0.003</td>
<td></td>
</tr>
<tr>
<td>Hypertension %</td>
<td>78.9</td>
<td>65.6</td>
<td>64.5</td>
<td>0.302</td>
<td></td>
</tr>
<tr>
<td>Previous transplant %</td>
<td>18.4</td>
<td>6.2</td>
<td>0</td>
<td>0.15</td>
<td></td>
</tr>
<tr>
<td>Peripheral vascular disease %</td>
<td>2.6</td>
<td>6.7</td>
<td>3.2</td>
<td>0.644</td>
<td></td>
</tr>
<tr>
<td>Warfarin %</td>
<td>7.9</td>
<td>15.6</td>
<td>10</td>
<td>0.472</td>
<td></td>
</tr>
<tr>
<td>Aspirin %</td>
<td>13.2</td>
<td>32.8</td>
<td>43.3</td>
<td>0.019</td>
<td></td>
</tr>
<tr>
<td>Clopidogrel %</td>
<td>2.6</td>
<td>1.6</td>
<td>16.7</td>
<td>0.007</td>
<td></td>
</tr>
<tr>
<td>Type of fistula formed&lt;sup&gt;b&lt;/sup&gt;</td>
<td>18/14/6</td>
<td>29/26/10</td>
<td>15/14/2</td>
<td>0.765</td>
<td></td>
</tr>
<tr>
<td>RCF/BCF/BBF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-dialysis&lt;sup&gt;c&lt;/sup&gt;</td>
<td>3/13/22</td>
<td>5/25/35</td>
<td>2/16/13</td>
<td>0.673</td>
<td></td>
</tr>
<tr>
<td>?/Pre/Post</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
*W=White; A=Asian; B=Black; M=Mixed; C=Chinese.

*RCF=Radiocephalic fistula; BCF=Brachiocephalic fistula; BBF=First stage brachoibasilic fistula.

?=?unknown dialysis status; Pre=pre-dialysis; Post=commenced dialysis.
Table II: Cumulative survival (%) at the end of the year

<table>
<thead>
<tr>
<th>Years</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group A (&lt;50 yr)</td>
<td>100</td>
<td>97.4</td>
<td>94.7</td>
<td>92.1</td>
</tr>
<tr>
<td>Group B (50-74 yr)</td>
<td>87.5</td>
<td>78.1</td>
<td>70.3</td>
<td>60.9</td>
</tr>
<tr>
<td>Group C (&gt;75yr)</td>
<td>70.9</td>
<td>58.1</td>
<td>51.6</td>
<td>45.2</td>
</tr>
</tbody>
</table>